Schering AG of Berlin and Avid Radiopharmaceuticals
Inc. of Philadelphia are collaborating to develop diagnostic imaging agents for
Alzheimer’s. The compounds, made by Avid, bind to amyloid plaques in the brain,
which are thought to cause the disease. The compounds can be used with noninvasive
imaging techniques such as PET. Under the agreement, Schering has the option to
assume exclusive rights for the development and commercialization of such compounds
for use with PET.
MORE FROM PHOTONICS MEDIA